Opinion: The Chemotherapy Shortage Is Hard to Wrap Your Head Around
“As an RN in a surgical oncology unit, I have cared for many patients receiving chemotherapy.”

When the Cancer Awakens
“My current treatment was successful in making sure it did not change or grow. I linked it to when a toddler has completely demolished the living room with toys and energy. Then it’s time for his nap. You clean up the mess, then settle in with a good cup of tea. That time with a cup of tea is like enjoying cancer’s stability. Except sooner or later, the toddler awakens. And recently, so did my cancer.”

Northwestern Medicine Launches a Hispanic Program for Patients With Lung and Thoracic Diseases
“The Northwestern Medicine Canning Thoracic Institute Hispanic Program was recently launched to offer personalized care for lung and thoracic patients in their native language, making life-saving care more accessible for the Hispanic community and people who prefer to speak Spanish by removing cultural and linguistic barriers.”

Mom, 35, diagnosed with stage 4 lung cancer shares the subtle warning signs she ignored for years
“A mother from California’s has revealed her cancer symptoms were blamed on anxiety and doctors said she should ‘see a therapist’.”

TTF Fields Improve Survival in Lung Cancer
“Adding Tumor Treating Fields (TTFields) to standard systemic therapy tended to improve survival in patients with metastatic non-small cell lung cancer (NSCLC) who had progression on or after platinum-based therapy, according to findings from the LUNAR trial that were recently published in The Lancet Oncology.

Lung cancer biomarker campaign, launched with AstraZeneca, boosts its reach and adds pharma supporters
“The groups are called the MET Crusaders, the EGFR Resistors, the KRAS Kickers and the ROS1ders — and members are non small cell lung cancer patients who share the same biomarkers. The groups, though, are also avid cancer biomarker testing advocates and supporters of LUNGevity’s “No One Missed” campaign to encourage comprehensive testing in lung cancer.”

Roche announces positive phase 3 results for Alecensa in early-stage lung cancer
“The phase 3 ALINA study has been evaluating the targeted drug as an adjuvant therapy in patients with completely resected stage 1B to 3A ALK-positive non-small cell lung cancer (NSCLC).”

National Comprehensive Cancer Network awards grants for small cell lung cancer research
“The funding — provided through support from AstraZeneca — is intended to support projects focused on reducing gaps in care for people with limited-stage or extensive-stage small cell lung cancer.”

Early Molecular Genotyping Testing Results Confer OS Benefit in Advanced NSCLC
“Patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) and available molecular genotyping results experienced a significant improvement in overall survival (OS) following first-line therapy compared with those with unavailable testing, according to findings from a real-world cohort study published in the Journal of Clinical Oncology Precision Oncology.”

New research could help improve the effectiveness of immunotherapy for people with brain tumors
“A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds new light on why tumors that have spread to the brain from other parts of the body respond to immunotherapy while glioblastoma, an aggressive cancer that originates in the brain, does not.”